CancerTools.org, a unique non-profit cancer research tool supplier and part of Cancer Research UK, has chosen Discovery Park as the home of their first UK based laboratory, growing their team at the Sandwich Science and Tech campus.
Since establishing its presence at Discovery Park in 2023, CancerTools.org has expanded its operations, enhancing its capacity to provide high-quality cancer research tools to the global scientific community. Many of these tools are contributed by leading academic laboratories and researchers, reflecting the organisation’s collaborative approach. The organisation…
New PhysioMimix in silico tools unlock deeper functional insights from existing assays, advancing translation of MPS data to predict human ADME behavior
End-to-end support from experimental design to data interpretation
Cambridge, UK, 02 September 2025: CN Bio, a leading provider of Organ-on-a-chip (OOC) Systems and solutions that accelerate drug discovery and development workflows, today announced the expansion of its Contract Research Services (CRS) with new PhysioMimix® computational modeling tools. These capabilities have been developed to enhance Absorption, Distribution,…
Targeted protein degradation experts Prof. Alessio Ciulli FRS and Dr Adam Gilbert appointed
SAB will provide strategic and scientific perspectives to support development of TRIMTAC and TRIMGLUE selective targeted protein degraders, and small molecule therapeutic pipeline
Cambridge, UK, 02 September 2025: TRIMTECH Therapeutics, a biotech company creating novel, small molecule therapeutics that selectively degrade protein aggregates, to combat neurodegenerative diseases, today announced the formation of its Scientific Advisory Board (SAB). Globally recognised leaders within the protein…
Members of the Industry Skills Accelerator (ISA) have celebrated a successful year of strengthening the UK’s medicines manufacturing workforce.
Launched in August 2024 and funded by Innovate UK, the ISA is a national initiative delivered through a partnership between Cogent Skills, the Cell and Gene Therapy Catapult (CGT Catapult), and CPI (part of the High Value Manufacturing Catapult).
Focused on advanced therapies and complex medicines – including cell, gene, vaccines, biologics, and other high-potential modalities such as mRNA and Oligonucleotides - the ISA is building targeted training…
LONDON, UK, and BOSTON, MA, September 2, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for AstriVax Therapeutics NV and is pleased to announce the placement of Dieter Weinand as Chair of its Board of Directors.AstriVax Therapeutics is a clinical stage immunotherapy company developing novel treatments for chronic infections based on its proprietary plug and play plasmid-based Launch-iT technology.US-based Dieter Weinand is the former Chief…
Appointment underscores Qureight’s commitment to drive adoption of its AI-powered imaging and clinical data curation platform to support clinical trials and accelerate drug development timelines for lung and heart diseases
Former big tech executive and NVIDIA director with proven track record of driving innovation in adoption of AI in life sciences and healthcare
Cambridge, UK, 01 September 2025 – Qureight, a techbio company advancing the understanding of lung and heart disease through application of its AI-powered imaging and clinical data curation platform, today announced the…
The trend of staff redundancies and company down-sizing is prevalent in most if not all established life science ecosystems as reported in the recent “Biotech layoffs in 2025: The Labiotech tracker”. One Nucleus members are far from immune to this phenomenon being experienced of course and we see numerous examples of member employees finding themselves back in the jobs market. Mindful of the impact, One Nucleus strives to support both the redundant employees and the companies in the unfortunate position to be laying people off in order to maximise the chances of redeployment.…
Asymchem has announced a significant expansion of its flow chemistry capabilities at its Sandwich, UK facility.
SANDWICH, UNITED KINGDOM, August 2025 - Asymchem, a global leader in contract development and manufacturing (CDMO) solutions, has announced a significant expansion of its flow chemistry capabilities at Discovery Park, in Sandwich, UK. This milestone marks the first deployment of Asymchem’s proprietary and CE marking flow equipment in the Western market that further strengthens the company’s position in the adoption of advanced flow chemistry technologies.
The newly commissioned…
The August edition of our People Pathways newsletter is now available to read here!
Featuring:✅ One Nucleus upcoming courses✅ New Training Opportunities - We would love to hear from you on this!✅ Building Networks, Supporting Careers: Insights from Our AugustRoundtables✅ A One Nucleus Skills Exchange Forum on WhatsApp – Seeking Opinion✅ Details on the University of Cambridge Life Sciences Fair 2025✅ Cogent Skills Enabling Businesses to Take on Apprentices in Uncertain Times
Qureight’s advanced AI 3D imaging platform to be used across clinical trial to evaluate anatomical lung changes in adult patients, including during patient enrolment
CAL101 is a first-in-class monoclonal antibody that neutralises the S100A4 protein, which is an upstream driver and amplifier of the multiple pro-fibrotic pathways active in IPF
Cambridge, UK, 27 August 2025 – Qureight, a techbio company advancing the understanding of lung and heart disease through application of its AI-powered imaging and clinical data curation platform, today announced that it has been selected by…